Form 4: Cryoport CSO Reports Equity Grants, Tax-Related Sale

Cryoport's Chief Scientific Officer, Mark W. Sawicki, reported the acquisition of restricted stock rights and stock options, alongside a tax-related sale of common stock.

Summary

• Mark W. Sawicki, Chief Scientific Officer of Cryoport, Inc. (CYRX), reported changes in his beneficial ownership.
• On March 14, 2026, Sawicki acquired 22,845 shares of common stock as restricted stock rights at a price of $0 per share.
• These restricted stock rights are contingent and will vest in four equal annual installments beginning March 14, 2027.
• On March 16, 2026, Sawicki disposed of 3,235 shares of common stock at a price of $8 per share.
• This disposition was a mandatory sale to cover taxes due upon the vesting of restricted stock rights, in accordance with Cryoport's policies.
• On March 14, 2026, Sawicki also acquired 68,534 stock options (right to buy) at a price of $0, with an exercise price of $8.6 per share.
• These stock options will vest at a rate of 1/48th each month for forty-eight months, commencing April 14, 2026, and expire on March 14, 2033.
• Following these transactions, Sawicki directly beneficially owns 103,697 shares of common stock and 68,534 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive. The equity grants align the CSO's interests with shareholders, while the tax-related sale is a neutral, routine event.

Positives

• The grant of 22,845 restricted stock rights and 68,534 stock options aligns the Chief Scientific Officer's interests with long-term shareholder value.
• Equity compensation at a $0 acquisition price for the grants indicates a strong incentive for future performance and retention.

Negatives

• The disposition of 3,235 shares, while for tax purposes, represents a reduction in direct common stock ownership.

Future Outlook

The filing indicates future vesting schedules for both restricted stock rights, commencing March 14, 2027, and stock options, commencing April 14, 2026, providing a long-term incentive structure for the Chief Scientific Officer.

Industry Context

StockSavvy.ai notes that the grant of restricted stock rights and stock options is a standard practice in the biotechnology and life sciences industry for executive compensation, aiming to retain key talent and align management incentives with long-term company performance and shareholder value. The 'sell to cover' transaction for taxes is also a common and expected event upon the vesting of such equity awards.

Comparison to Industry Standards

• Equity grants, such as restricted stock units and stock options, are a prevalent form of executive compensation across the biotech and specialized logistics sectors, similar to practices observed at companies like Bio-Techne Corporation or Catalent, Inc.
• The vesting schedules (four years for restricted stock, four years for options) are typical for executive equity awards, designed to encourage long-term commitment and performance, aligning with benchmarks seen in comparable roles at industry peers.
• The 'sell to cover' transaction for tax obligations upon vesting is a standard mechanism, widely adopted by executives in publicly traded companies to manage tax liabilities without requiring personal cash outlays, consistent with practices at companies across various sectors.

Stakeholder Impact

• Shareholders: The equity grants provide an incentive for the Chief Scientific Officer to drive long-term company performance, potentially benefiting shareholders. The grants also represent a minor potential for future dilution upon exercise/vesting.
• Employees (Chief Scientific Officer): The grants serve as a significant component of the CSO's compensation, aligning their financial interests with the company's success and providing retention incentives.

Next Steps

• Continued vesting of 22,845 restricted stock rights in four equal annual installments beginning March 14, 2027.
• Continued vesting of 68,534 stock options at a rate of 1/48th each month for forty-eight months, beginning April 14, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider equity compensation grants and a tax-related sale, which are standard events for executive officers. These transactions do not fundamentally alter the company's financial outlook or strategic direction, thus a 'hold' recommendation is appropriate as the filing itself does not present new information warranting a change in investment thesis.

Keywords

Cryoport, CYRX, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Rights, Stock Options, Chief Scientific Officer, Beneficial Ownership